{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:57:44Z","timestamp":1790834264097,"version":"4.1.0"},"reference-count":19,"publisher":"European Respiratory Society (ERS)","issue":"6","funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2015,7,22]]},"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:p>\n                    In SERAPHIN, a long-term, randomised, controlled trial (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00660179\">NCT00660179<\/jats:ext-link>\n                    ) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity\/mortality and PAH-related death\/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-na\u00efve incident and prevalent cohorts.\n                  <\/jats:p>\n                  <jats:p>Patients allocated to placebo, or macitentan 3\u2005mg or 10\u2005mg were classified by time from diagnosis to enrolment as incident (\u22646\u2005months; n=110) or prevalent (&gt;6\u2005months; n=157). The risk of morbidity\/mortality and PAH-related death\/hospitalisation was determined using Cox regression.<\/jats:p>\n                  <jats:p>\n                    The risk of morbidity\/mortality (Kaplan\u2013Meier estimates at month 12: 54.4%\n                    <jats:italic>versus<\/jats:italic>\n                    26.7%; p=0.006) and PAH-related death\/hospitalisation (Kaplan\u2013Meier estimates at month 12: 47.3%\n                    <jats:italic>versus<\/jats:italic>\n                    19.9%; p=0.006) were significantly higher for incident\n                    <jats:italic>versus<\/jats:italic>\n                    prevalent patients receiving placebo, respectively. There was no significant difference in the risk of all-cause death between incident and prevalent cohorts (p=0.587). Macitentan 10\u2005mg significantly reduced the risk of morbidity\/mortality and PAH-related death\/hospitalisation\n                    <jats:italic>versus<\/jats:italic>\n                    placebo in incident and prevalent cohorts.\n                  <\/jats:p>\n                  <jats:p>Incident patients had a higher risk for PAH progression compared with prevalent patients but not a higher risk of death. Macitentan delayed disease progression in both incident and prevalent PAH patients.<\/jats:p>","DOI":"10.1183\/13993003.00364-2015","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T14:42:18Z","timestamp":1445870538000},"page":"1711-1720","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN"],"prefix":"10.1183","volume":"46","author":[{"given":"G\u00e9rald","family":"Simonneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Channick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Delcroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Gali\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein-Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Jansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck-Olivier","family":"Le Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Perchenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.K.S.","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rog\u00e9rio","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2015,10,22]]},"reference":[{"key":"2024102023440017000_46.6.1711.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp022"},{"key":"2024102023440017000_46.6.1711.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057010"},{"key":"2024102023440017000_46.6.1711.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.911818"},{"key":"2024102023440017000_46.6.1711.4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"2024102023440017000_46.6.1711.5","first-page":"A4741","article-title":"Five-year outcomes of the Registry To Evaluate Early And Long-Term Pulmonary Arterial Hypertension (PAH) Disease Management (REVEAL).","volume":"183","author":"Miller","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102023440017000_46.6.1711.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.023"},{"key":"2024102023440017000_46.6.1711.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00094112"},{"key":"2024102023440017000_46.6.1711.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047662"},{"key":"2024102023440017000_46.6.1711.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107809"},{"key":"2024102023440017000_46.6.1711.10","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.142976"},{"key":"2024102023440017000_46.6.1711.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2014.02.018"},{"key":"2024102023440017000_46.6.1711.12","unstructured":"Actelion Pharmaceuticals US, Inc. Opsumit (macitentan) prescribing information. https:\/\/opsumit.com\/sites\/opsumit\/files\/OPSUMIT-Full-Prescribing-Information.pdf Date last accessed: March, 2015. Date last updated: April, 2015."},{"key":"2024102023440017000_46.6.1711.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"2024102023440017000_46.6.1711.14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-14-45"},{"key":"2024102023440017000_46.6.1711.15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00101211"},{"key":"2024102023440017000_46.6.1711.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00042107"},{"key":"2024102023440017000_46.6.1711.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.034"},{"key":"2024102023440017000_46.6.1711.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2871"},{"key":"2024102023440017000_46.6.1711.19","first-page":"511","article-title":"Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases","volume":"6","author":"Kelsey","year":"1997","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00364-2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:59:40Z","timestamp":1740362380000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00364-2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,22]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,11,30]]},"published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1183\/13993003.00364-2015"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00364-2015","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725872771.793525232","asserted-by":"object"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,22]]}}}